•
Mar 30
Johnson & Johnson Q1 2025 Earnings Report
Johnson & Johnson reported strong earnings with significant net income growth and progress in its product pipeline during Q1 2025.
Key Takeaways
Johnson & Johnson delivered solid financial performance in Q1 2025, driven by growth across key product lines in Innovative Medicine and MedTech. Net income surged due to the reversal of special charges, and the company advanced its innovation strategy with key regulatory approvals and clinical trial initiations.
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson Revenue by Segment
Johnson & Johnson Revenue by Geographic Location
Forward Guidance
Johnson & Johnson raised its 2025 sales guidance following the acquisition of Intra-Cellular Therapies and reaffirmed its EPS outlook.
Positive Outlook
- Increased full-year operational sales guidance to reflect CAPLYTA acquisition
- Strong momentum in oncology and immunology portfolios
- New product approvals including TREMFYA for Crohn's disease
- Initiation of OTTAVA robotic system clinical trial
- Robust pipeline progress in neuroscience and autoimmune therapies
Challenges Ahead
- Headwinds from STELARA biosimilar competition impacting immunology sales
- Decline in international sales due to currency and prior-year comps
- Lower growth in orthopaedics and electrophysiology
- Pressure on legacy neuroscience products like INVEGA
- Expected dilution from Intra-Cellular Therapies acquisition
Revenue & Expenses
Visualization of income flow from segment revenue to net income